Condition: Breast Cancer · Breast Neoplasms · Breast Cancers · Sponsor: Baylor Research Institute
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.
This description comes directly from the study's public registry record.
CORC Solid Tumor · 214-818-8472 · corcsolidtumor@bswhealth.org
Page E Blas, MA · 214-820-5424 · page.blas@bswhealth.org
Always discuss trial participation with your own doctor first.
| Baylor University Medical Center, Baylor Charles A Sammons Cancer Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06517212